Gabapentin Tablet
Product Images NDC 68788-8468

7 FDA label images from Preferred Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-8468). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clcr (Equation)

Clcr (Equation)
A formula representing creatinine clearance calculation (CLCr) using age, weight, serum creatinine, and a factor for female patients. This formula is commonly used to estimate kidney function relevant to drug dosing.*
FDA Label Image

Struc (Struct)

Struc (Struct)
Chemical structure of gabapentin, showing a cyclohexane ring attached to a carbon bonded to an amino group (CH2NH2) and a carboxyl group (CH2CO2H).*
FDA Label Image

Figure-1 (Figure1)

Figure-1 (Figure1)
A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1' comparing mean pain scores over 8 weeks between placebo and Gabapentin 3600 mg/day groups. The x-axis represents weeks, and the y-axis shows mean pain scores from 0 to 10. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period, illustrating a decrease in pain scores for the Gabapentin group versus stable scores for placebo.*
FDA Label Image

Figure-2 (Figure2)

Figure-2 (Figure2)
A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' showing mean pain scores over 7 weeks. It compares three groups: Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The graph indicates a 3-week dose titration period followed by a 4-week fixed dose period, with pain scores decreasing more for the Gabapentin groups than placebo over time.*
FDA Label Image

Figure-3 (Figure3)

Figure-3 (Figure3)
A bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) at various dosages in two studies. Study 1 shows 12% responder rate for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg, with statistical significance indicated for gabapentin groups.*
FDA Label Image

Figure-4 (Figure4)

Figure-4 (Figure4)
A scatter plot figure titled "Responder Rate in Patients Receiving Gabapentin Expressed as a Difference from Placebo by Dose and Study," showing the relationship between daily gabapentin dose (600, 900, 1200, 1800 mg) on the x-axis and responder rate difference (%) on the y-axis. The graph includes data points from three studies labeled a, b, and c, with distinct square markers and annotations for each dose group.*
FDA Label Image

Gabapentin Tablets Usp 800mg (800 mg 500s)

Gabapentin Tablets Usp       800mg (800 mg 500s)
Packaging label for Gabapentin Tablets, USP 800 mg, a generic for Neurontin. The label shows the drug strength (800 mg) and dosage form (tablet) with instructions available in English and Spanish. Manufacturer information lists Ascent Pharmaceuticals, Inc. There are fields for Expiration Date, Lot Number, and Batch Number, along with storage and cautionary warnings. The label also includes barcodes and a QR code for product identification.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.